← Leaderboards
Nicholas James Mullen
University Of Nebraska Medical Center
$180,660
Attributed
$180,660
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54K · FY2021–24$100K$75K$50K$25K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$180,660 · 1
By mechanism
F30$180,660 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Maneesh Jain$6,905,007
- Ravi Salgia$9,622,551
- Michael A Hollingsworth$34,707,253
- Alexander V Kabanov$28,176,125
- Ram I Mahato$10,713,899
Others in their field
Other Emerging Leaders on “Combinatorial”
- Bryan Roth · Univ Of North Carolina Chapel Hill$12,367,722
- Paul John Norman · University Of Colorado Denver$8,178,212
- Ansuman Satpathy · Stanford University$7,721,054
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Liangcai Gu · University Of Washington$6,742,121
Research focus
CombinatorialAbraxaneCombatAnabolismAnimal ModelAgammaglobulinaemia Tyrosine KinaseAmericanAffectAntineoplastic AgentsAutomobile DrivingBaseBiochemicalCancer CellCancer EtiologyCancer TypeCell LineCell ProliferationCellsCell SurvivalCessation Of LifeChemotherapyClinical EffectivenessClinical TrialsCombined Modality Therapy
Grant awards (4)
Targeting pyrimidine biosynthesis in pancreatic ductal adenocarcinoma$53,974
F30 · FY2024 · CA · contact PI
Targeting pyrimidine biosynthesis in pancreatic ductal adenocarcinoma$52,694
F30 · FY2023 · CA · contact PI
Targeting pyrimidine biosynthesis in pancreatic ductal adenocarcinoma$37,354
F30 · FY2022 · CA · contact PI
Targeting pyrimidine biosynthesis in pancreatic ductal adenocarcinoma$36,638
F30 · FY2021 · CA · contact PI